News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Maxygen, Inc. Says Drug Under Amgen Patent Cloud
June 13, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BANGALORE, June 13 (Reuters) - Shares of biotechnology firm Maxygen Inc slid as much as 30 percent after news that it could face a legal patent battle with sector leader Amgen Inc over its lead cancer drug.
Twitter
LinkedIn
Facebook
Email
Print
Asia
Amgen
MORE ON THIS TOPIC
Podcast
Tariffs Continue to Dominate Q1 Earnings, AACR Excites Cancer Space, CEO Pay Gaps, More
April 30, 2025
·
1 min read
·
Heather McKenzie
Tariffs
China Still Go-To Source for New Drugs Despite Tariff Minefield
April 30, 2025
·
10 min read
·
Annalee Armstrong
Cancer
Summit, Akeso’s Keytruda Challenger Wins Chinese OK as US Approval Questions Linger
April 28, 2025
·
3 min read
·
Tristan Manalac
Lung cancer
Summit’s Bispecific Beats Yet Another Cancer Med, Pressuring Keytruda’s ‘Supremacy’
April 23, 2025
·
2 min read
·
Tristan Manalac
